Critical Illness Myopathy: Glucocorticoids revisited?

Z'Graggen, Werner Josef; Schefold, Joerg C. (2019). Critical Illness Myopathy: Glucocorticoids revisited? Acta physiologica, 225(2), e13205. Blackwell Publishing 10.1111/apha.13205

[img]
Preview
Text
2018 - Z'Graggen - Acta Physiol - PMID 30338655.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (72kB) | Preview

Over the past decades, survival rates of critical illness have constantly increased. As a consequence, the incidences of important complications of intensive care unit (ICU) treatment become more and more prevalent. Critical illness myopathy (CIM) belongs to one of the most frequent neuromuscular complications and its presence is associated with prolonged need for mechanical ventilation and ICU stay, increased morbidity and mortality 1,2. High-dose glucocorticoid (GC) treatment was early after the initial description of CIM postulated to be a major triggering factor for the development of the disease. In the current issue of Acta Physiologica, Akkad et al. investigate the effects of two GC drugs (prednisolone and a new dissociative GC termed vamorolone) on CIM development3. This article is protected by copyright. All rights reserved.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurosurgery
04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic of Intensive Care

UniBE Contributor:

Z'Graggen, Werner Josef and Schefold, Joerg C.

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1748-1708

Publisher:

Blackwell Publishing

Language:

English

Submitter:

Mirella Aeberhard

Date Deposited:

23 Oct 2018 13:43

Last Modified:

23 Oct 2019 02:45

Publisher DOI:

10.1111/apha.13205

PubMed ID:

30338655

BORIS DOI:

10.7892/boris.120577

URI:

https://boris.unibe.ch/id/eprint/120577

Actions (login required)

Edit item Edit item
Provide Feedback